ArticleProceedings of the National Academy of Sciences of the United States of America2019
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 127 citations in OpenAlex.
- Hypoxia-mediated epicardial signaling coordinates coronary angiogenesis and myocardial expansion during zebrafish ventricle maturation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Solute Carrier transporters in tumor metabolism and immune modulation: implications for therapy.Journal of translational medicine · 2026Review
- Sanguinarine and Doxorubicin Inhibit Heat Shock Protein HSPA5 and Trigger ER Stress in Breast Cancer.Cell biochemistry and biophysics · 2026Article
- HDAC4 Promotes Cancer Stemness in Nonsmall Cell Lung Cancer by Upregulating SLC38A2 Expression via HIF-1α to Enhance Glutamine Metabolism.Analytical cellular pathology (Amsterdam) · 2026Article
- Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Advances in experimental medicine and biology · 2026Review
- Inhibition of apoptosis in breast cancer cells by si-FoxO3a through the protein digestion and absorption signaling pathway.Oncology letters · 2025Article
- Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications.Discover oncology · 2025Review
- Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy.Cell death discovery · 2025Review
- The HIF axes in cancer: angiogenesis, metabolism, and immune-modulation.Trends in biochemical sciences · 2025Review
- Amino acid metabolism in breast cancer: pathogenic drivers and therapeutic opportunities.Protein & cell · 2025Review
- Targeting EPAS-1/HIF-2α Pathway to Address Endocrine Resistance in Luminal A Type Breast Cancer.Translational oncology · 2025Article
- Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches.Cell reports · 2025Review
- Metabolic signatures in gastroenteropancreatic neuroendocrine neoplasms: unraveling diagnostic and prognostic insights.Frontiers in endocrinology · 2025Review
- Panoramic analysis of the biological function and clinical value of SLC38A2 in human cancers: a study based on pan-cancer and single-cell analysis.Frontiers in genetics · 2025Article
- Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets.Frontiers in pharmacology · 2025Review
- miR-10b-5p promotes tumor growth by regulating cell metabolism in liver cancer via targeting SLC38A2.Cancer biology & therapy · 2024Article
- The signature of extracellular vesicles in hypoxic breast cancer and their therapeutic engineering.Cell communication and signaling : CCS · 2024Review
- Transcriptomic and Proteomic Insights into Host Immune Responses in Pediatric Severe Malarial Anemia: Dysregulation in HSP60-70-TLR2/4 Signaling and Altered Glutamine Metabolism.Pathogens (Basel, Switzerland) · 2024Article
- ASCT2 is a major contributor to serine uptake in cancer cells.Cell reports · 2024Article
- LAT1 expression in colorectal cancer cells is unresponsive to HIF-1/2α accumulation under experimental hypoxia.Scientific reports · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 3 countries.
Matteo MorottiHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom; drmorottimatteo@gmail.com aharris.lab@imm.ox.ac.uk.ORCID 0000-0002-1790-1185
Esther BridgesHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Alessandro ValliHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Hani ChoudhryDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah F6VM+J2, Saudi Arabia.
Helen SheldonHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Simon WigfieldHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Nicki GrayComputational Biology Research Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, United Kingdom.
Christos E ZoisHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Fiona GrimmCancer Metabolism Laboratory, Francis Crick Institute, London NW1 1ST, United Kingdom.
Dylan JonesHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Eugene J TeohHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Wei-Chen ChengComputational Biology and Integrative Genomics, Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Simon LordHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Dimitrios AnastasiouCancer Metabolism Laboratory, Francis Crick Institute, London NW1 1ST, United Kingdom.
Syed HaiderComputational Biology and Integrative Genomics, Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Alan McIntyreHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom.
Deborah C I GoberdhanDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, United Kingdom.
Francesca BuffaComputational Biology and Integrative Genomics, Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Adrian L HarrisHypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, United Kingdom; drmorottimatteo@gmail.com aharris.lab@imm.ox.ac.uk.
Cancer Research UK · GBThe Francis Crick Institute · GBUniversity of Oxford · GBInstitute of Cancer Research · GBJohn Radcliffe Hospital · GBKing Abdulaziz University · SAUniversity of California San Diego · USUniversity of Nottingham · GB
Funding
Cancer Research UK 18974Cancer Research UK 19076Cancer Research UK 23969Cancer Research UK FC001033Department of HealthMedical Research Council FC001033Medical Research Council MC_PC_15065Medical Research Council MC_UP_1202/1Medical Research Council MR/P010334/1Wellcome TrustWellcome Trust FC001033
Abstract
Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α-positive (ERα
Indexed as
Cell HypoxiaDrug Resistance, NeoplasmAmino Acid Transport System AAnimalsAntineoplastic Agents, HormonalBreast NeoplasmsCell Line, TumorEstrogen Receptor alphaEstrogen Receptor ModulatorsFemaleHeterograftsHumansMiceTumor MicroenvironmentAmino Acid Transport System AAntineoplastic Agents, HormonalESR1 protein, humanEstrogen Receptor alphaEstrogen Receptor ModulatorsSLC38A2 protein, humanamino acid transporterbreast cancercancer metabolismERαhypoxia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.